Doses of reality.
The Serum Institute of India, the world9s largest vaccinemaker, was poised to be the largest supplier of low-cost COVID-19 vaccines. But because of the surge of cases in India that began in late March, the company stopped exporting doses. The COVID-19 Vaccines Global Access (COVAX) Facility, a nonprofit set up to purchase and distribute vaccines equitably, found itself short of 90 million doses it had hoped to deliver by the end of May to low- and middle-income countries. Some say the Indian government could have avoided this dilemma had it prepurchased vaccines from many companies, as several countries did, and did not rely so heavily on Serum for its domestic needs. Adar Poonawalla, CEO of the family-owned business, urges other companies to supply COVAX with their own authorized products. Serum has recently increased capacity, but the company now says it may not export until the end of the year, further complicating efforts for COVAX and the world at large.